Fig. 1

ANGPTL3 is preferentially upregulated in sorafenib-responsive renal cell carcinoma. a qRT-PCR analysis of ANGPTL3 mRNA levels and the IC50 of sorafenib in 7 RCC cell lines (n = 3). b The mRNA expression levels of ANGPTL 3 in an independent set of RCC tumours samples with 10 good and 10 poor responses to sorafenib therapy (n = 3). c Western blot analysis of ANGPTL3 protein level in the 7 RCC cell lines. On the right is a graph of ANGPTL3 relative expression and the IC50 of sorafenib (n = 3). d Representative western blot results for ANGPTL3 protein levels in the pretherapy tumour tissues from RCC patients with good responses (n = 10) or poor responses (n = 10) to sorafenib therapy. The chart on the right shows the relative expressions of ANGPTL3. e qRT-PCR analysis of ANGPTL3 mRNA levels in the pretherapy tumour tissues of RCC patients with good responses (n = 32) or poor responses (n = 36) to sorafenib therapy (p = 0.002). f Immunohistochemical analysis of ANGPTL3 protein level in RCC tissues before sorafenib therapy. Representative immunohistochemistry images from patients who were non-responsive (N1, N2, N3) and responsive (R1, R2, R3) to sorafenib are shown. The scale bar represents 100 μm. g Percentages of non-responsive and responsive to sorafenib samples between different ANGPTL3 levels. Results are presented as the means ± SD. *p < 0.05, **p < 0.01. See also Supplementary Figure 1 and Supplementary Table 1-2